National CineMedia (NASDAQ:NCMI – Get Free Report)‘s stock had its “neutral” rating restated by equities researchers at Wedbush in a note issued to investors on Monday, RTT News reports. They currently have a $7.50 target price on the business services provider’s stock, up from their prior target price of $6.00. Wedbush’s price target points to a potential upside of 5.34% from the company’s current price.
Other analysts also recently issued reports about the company. B. Riley upped their price objective on National CineMedia from $7.50 to $8.50 and gave the stock a “buy” rating in a report on Friday, August 16th. Benchmark reissued a “buy” rating and issued a $8.00 price objective on shares of National CineMedia in a research report on Monday, September 23rd. Finally, Barrington Research raised shares of National CineMedia from a “market perform” rating to an “outperform” rating and set a $7.50 price objective for the company in a research report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.88.
Get Our Latest Stock Analysis on NCMI
National CineMedia Trading Down 0.7 %
National CineMedia (NASDAQ:NCMI – Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The business services provider reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The business had revenue of $54.70 million during the quarter, compared to analyst estimates of $49.87 million. National CineMedia had a net margin of 78.04% and a return on equity of 3.50%. During the same quarter last year, the firm posted ($0.07) earnings per share. Equities analysts expect that National CineMedia will post -0.05 EPS for the current fiscal year.
Institutional Trading of National CineMedia
Large investors have recently added to or reduced their stakes in the business. First Eagle Investment Management LLC boosted its stake in shares of National CineMedia by 37.6% during the 1st quarter. First Eagle Investment Management LLC now owns 1,966,355 shares of the business services provider’s stock valued at $10,127,000 after buying an additional 537,822 shares during the period. Harbor Capital Advisors Inc. boosted its stake in shares of National CineMedia by 270.0% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 208,649 shares of the business services provider’s stock valued at $916,000 after buying an additional 152,251 shares during the period. Rhumbline Advisers acquired a new stake in shares of National CineMedia during the 2nd quarter valued at $427,000. Bank of New York Mellon Corp acquired a new stake in shares of National CineMedia during the 2nd quarter valued at $979,000. Finally, Oppenheimer Asset Management Inc. boosted its stake in shares of National CineMedia by 38.9% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 23,897 shares of the business services provider’s stock valued at $123,000 after buying an additional 6,690 shares during the period. 69.49% of the stock is currently owned by institutional investors.
National CineMedia Company Profile
National CineMedia, Inc, through its subsidiary, National CineMedia, LLC, operates cinema advertising network in North America. It engages in the sale of advertising to national, regional, and local businesses in Noovie, a cinema advertising and entertainment show seen on movie screens; and sells advertising on its Lobby Entertainment Network, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theatre lobbies.
Further Reading
- Five stocks we like better than National CineMedia
- How Technical Indicators Can Help You Find Oversold Stocks
- Intel: Is Now the Time to Be Brave?
- Want to Profit on the Downtrend? Downtrends, Explained.
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Find and Profitably Trade Stocks at 52-Week Lows
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for National CineMedia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National CineMedia and related companies with MarketBeat.com's FREE daily email newsletter.